



**1 June 2022**

***The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.***

**OMEGA DIAGNOSTICS GROUP PLC**  
("Omega" or the "Company" or the "Group")

### **Result of Open Offer**

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces the results of its Open Offer.

On 6 May 2022, Omega announced its intention to raise gross proceeds of up to £4.1 million by way of a Placing, Subscription and Open Offer (together the "**Fundraising**"), all at an issue price of 4 pence per New Ordinary Share.

The Open Offer closed for acceptances at 11:00 a.m. on 31 May 2022. The Company has received valid acceptances from Qualifying Shareholders in respect of their Basic Entitlements in respect of 1,560,453 New Ordinary Shares and has also received applications from Qualifying Shareholders under the Excess Application Facility in respect of 1,317,323 New Ordinary Shares. In aggregate this totals 2,877,776 New Ordinary Shares, representing approximately 5.77 per cent. of the Open Offer Shares. Accordingly, Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full Basic Entitlements as well as those applied for under the Excess Application Facility.

Accordingly, a total of 5,002,776 New Ordinary Shares will be issued at the Issue Price (subject to the conditions noted below), of which, 2,125,000 New Ordinary Shares will be issued pursuant to the Subscription and 2,877,776 New Ordinary Shares will be issued pursuant to the Open Offer (the "**Open Offer Shares**"). This brings the gross proceeds of the Fundraising (including the Placing announced 6 May 2022) to £2.20 million before expenses.

### **General Meeting**

The Open Offer and Subscription remain conditional on the approval by Shareholders of the Resolutions at the Company's General Meeting to be held on 6 June 2022 (or any adjournment thereof), the satisfaction of certain conditions in the Placing Agreement and Admission of the New Ordinary Shares to trading on AIM occurring at or before 8.00 a.m. on 8 June 2022 (or such later date as the Company and finnCap may agree, being not later than 8.00 a.m. on 22 June 2022).

The Company will announce the results of the General Meeting as soon as practicable after the meeting concludes.

***Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 13 May 2022.***

### **Contacts:**

**Omega Diagnostics Group PLC**  
Jag Grewal, Chief Executive Officer  
Chris Lea, Chief Financial Officer

[www.omegadx.com](http://www.omegadx.com)  
via Walbrook PR

**finnCap Ltd**  
Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)  
Alice Lane/ Harriet Ward (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)

Paul McManus  
Lianne Applegarth  
Sam Allen

Mob: 07980 541 893  
Mob: 07584 391 303  
Mob: 07502 558 258

**About Omega Diagnostics Group PLC**

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

[www.omegadx.com](http://www.omegadx.com)